SPARC appoints Anil Raghavan as new CEO, Dilip Shanghvi resigns as MD
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Tuesday said Dilip Shanghvi has resigned as managing director of the company.
Shanghvi expressed his desire to step down and tendered his resignation as the MD with immediate effect, which was accepted by the board, SPARC said in a regulatory filing.
Shanghvi will, however, continue to be associated with the company''s board in his capacity as a non-executive director and chairman, it added.
It further stated that the board, on the recommendation of Nomination and Remuneration Committee, has appointed Anil Raghavan as chief executive officer (CEO) of the company with immediate effect for a term of five years till May 24, 2026.
Prior to joining SPARC, Raghavan served as the managing director of the India and Sri Lanka business of Quintiles, a global pharmaceutical services company.
SPARC was formed in 2007 through a demerger from drug major Sun Pharma.
Read also: SPARC reports positive results from Phase 3 trial of ocular hypertension treatment
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.